JP2013527232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013527232A5 JP2013527232A5 JP2013513207A JP2013513207A JP2013527232A5 JP 2013527232 A5 JP2013527232 A5 JP 2013527232A5 JP 2013513207 A JP2013513207 A JP 2013513207A JP 2013513207 A JP2013513207 A JP 2013513207A JP 2013527232 A5 JP2013527232 A5 JP 2013527232A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- bladder cancer
- administered
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 48
- 206010005003 Bladder cancer Diseases 0.000 claims 17
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 14
- 201000005112 urinary bladder cancer Diseases 0.000 claims 14
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 10
- 239000002105 nanoparticle Substances 0.000 claims 6
- 102000009027 Albumins Human genes 0.000 claims 5
- 108010088751 Albumins Proteins 0.000 claims 5
- 229910052697 platinum Inorganic materials 0.000 claims 5
- 229940123237 Taxane Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39680010P | 2010-06-02 | 2010-06-02 | |
| US61/396,800 | 2010-06-02 | ||
| US201161449513P | 2011-03-04 | 2011-03-04 | |
| US61/449,513 | 2011-03-04 | ||
| PCT/US2011/037449 WO2011153009A1 (en) | 2010-06-02 | 2011-05-20 | Methods of treating bladder cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013527232A JP2013527232A (ja) | 2013-06-27 |
| JP2013527232A5 true JP2013527232A5 (enExample) | 2014-07-03 |
Family
ID=45067028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513207A Pending JP2013527232A (ja) | 2010-06-02 | 2011-05-20 | 膀胱がんの処置方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20130266659A1 (enExample) |
| EP (1) | EP2575803B1 (enExample) |
| JP (1) | JP2013527232A (enExample) |
| KR (1) | KR20130109025A (enExample) |
| CN (1) | CN103221042B (enExample) |
| AU (1) | AU2011261684B2 (enExample) |
| BR (1) | BR112012030699A2 (enExample) |
| CA (1) | CA2801314A1 (enExample) |
| CO (1) | CO6620019A2 (enExample) |
| CR (1) | CR20120619A (enExample) |
| ES (1) | ES2639038T3 (enExample) |
| MX (1) | MX343671B (enExample) |
| MY (1) | MY188911A (enExample) |
| NI (1) | NI201200175A (enExample) |
| NZ (2) | NZ708506A (enExample) |
| PH (2) | PH12012502378A1 (enExample) |
| RU (1) | RU2621640C2 (enExample) |
| SG (1) | SG186109A1 (enExample) |
| WO (1) | WO2011153009A1 (enExample) |
| ZA (1) | ZA201208815B (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| CA2509365C (en) | 2002-12-09 | 2012-08-07 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| KR20070114753A (ko) | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| LT3311805T (lt) * | 2005-08-31 | 2020-04-27 | Abraxis Bioscience, Llc | Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| EP2131821B1 (en) * | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| JP5579057B2 (ja) | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | 再発性癌の処置のための方法および組成物 |
| PT2419732T (pt) | 2009-04-15 | 2019-12-24 | Abraxis Bioscience Llc | Composições e métodos de nanopartículas isentas de priões |
| NZ602382A (en) | 2010-03-26 | 2014-11-28 | Abraxis Bioscience Llc | Methods of treatment of hepatocellular carcinoma |
| MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
| EP3141245A1 (en) | 2010-03-29 | 2017-03-15 | Abraxis BioScience, LLC | Methods of treating cancer |
| EP2569633B1 (en) | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| MX347225B (es) | 2010-06-04 | 2017-04-19 | Abraxis Bioscience Llc * | Metodos de tratamiento contra el cancer pancreatico. |
| JP6031437B2 (ja) * | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス， エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
| KR101970342B1 (ko) | 2011-04-28 | 2019-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| DK177379B1 (en) * | 2012-03-29 | 2013-02-25 | Entomopharm Aps | Insect-based model to study the effect and integrity of nanoparticles on blood-brain barrier function |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140199404A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| JP6387389B2 (ja) * | 2013-03-13 | 2018-09-05 | アブラクシス バイオサイエンス， エルエルシー | 小児充実性腫瘍の処置の方法 |
| RU2015143490A (ru) * | 2013-03-14 | 2017-04-26 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| US20150250717A1 (en) | 2014-03-06 | 2015-09-10 | Taris Biomedical Llc | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine |
| WO2015018380A2 (en) * | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Therapeutic nanoparticles and the preparation methods thereof |
| EP3234130B1 (en) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| IL294183B2 (en) | 2015-05-20 | 2023-10-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| CA3026454C (en) | 2015-06-04 | 2023-07-04 | Crititech, Inc. | Collection device and methods for use |
| KR20240144442A (ko) * | 2015-06-29 | 2024-10-02 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물에 대한 바이오마커 |
| ES3009356T3 (en) | 2015-06-29 | 2025-03-26 | Abraxis Bioscience Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| EP3328380A4 (en) * | 2015-07-31 | 2019-07-24 | Pharmacyclics LLC | INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF |
| EP3854381A1 (en) | 2016-04-04 | 2021-07-28 | Crititech, Inc. | Methods for solid tumor treatment |
| CN118453872A (zh) * | 2016-05-06 | 2024-08-09 | 塔里斯生物医药公司 | 治疗下尿路尿道上皮癌的方法 |
| US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| CA3058807A1 (en) | 2017-04-03 | 2018-10-11 | Biontech Us Inc. | Protein antigens and uses thereof |
| CA3063420A1 (en) | 2017-06-09 | 2018-12-13 | Crititech, Inc. | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
| WO2018231908A1 (en) | 2017-06-14 | 2018-12-20 | Crititech, Inc. | Methods for treating lung disorders |
| SG10201913998YA (en) | 2017-07-25 | 2020-03-30 | Taris Biomedical Llc | Methods of treating tumor metastasis |
| KR20250057947A (ko) | 2017-10-03 | 2025-04-29 | 크리티테크, 인크. | 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달 |
| IL302714B1 (en) | 2017-11-08 | 2026-01-01 | Taris Biomedical Llc | Methods for treating and maintaining bladder cancer using gemcitabine |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| EP3735220A1 (en) * | 2018-01-05 | 2020-11-11 | Crititech, Inc. | Treatment of bladder cancer by local administration of taxane particles |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| MX2020014243A (es) | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| WO2020072090A1 (en) * | 2018-10-03 | 2020-04-09 | Crititech, Inc. | Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls) |
| BR112022007710A2 (pt) | 2019-10-28 | 2022-07-12 | Abraxis Bioscience Llc | Composições farmacêuticas de albumina e rapamicina |
| TW202428262A (zh) * | 2022-11-09 | 2024-07-16 | 美商坦帕斯醫療公司 | 三唑酮化合物及其用途 |
| US12531162B1 (en) * | 2023-05-31 | 2026-01-20 | Northeastern University | Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net |
| US12562256B2 (en) * | 2023-11-07 | 2026-02-24 | New York University | Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| CA2472404A1 (en) * | 1993-07-19 | 1995-02-02 | Angiotech Pharmaceuticals, Inc. | Combination of stent and anti-angiogenic factor |
| GB9811598D0 (en) * | 1998-05-30 | 1998-07-29 | Imp College Innovations Ltd | Diagnosis and treatment of cancer |
| CA2509365C (en) | 2002-12-09 | 2012-08-07 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| RU2361615C2 (ru) * | 2002-12-09 | 2009-07-20 | Абраксис Байосайенс, Ллс. | Композиции и способы доставки фармакологических агентов |
| AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| KR20070114753A (ko) * | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| EP3527202A1 (en) | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| ES2389828T3 (es) * | 2007-04-13 | 2012-11-02 | Abraxis Bioscience, Inc. | Composiciones que comprenden polipéptidos SPARC |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| CA2746129A1 (en) * | 2008-12-11 | 2010-06-17 | Abraxis Bioscience, Llc | Combination chemotherapy of nanoparticulate taxanes and inhibitors of pro-survival and/or inflammatory signals |
| EP3103452A1 (en) * | 2009-08-25 | 2016-12-14 | Abraxis BioScience, LLC | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
-
2011
- 2011-05-20 CA CA2801314A patent/CA2801314A1/en not_active Abandoned
- 2011-05-20 EP EP11790192.6A patent/EP2575803B1/en not_active Revoked
- 2011-05-20 WO PCT/US2011/037449 patent/WO2011153009A1/en not_active Ceased
- 2011-05-20 MX MX2012013909A patent/MX343671B/es active IP Right Grant
- 2011-05-20 KR KR1020127034199A patent/KR20130109025A/ko not_active Ceased
- 2011-05-20 MY MYPI2012005167A patent/MY188911A/en unknown
- 2011-05-20 SG SG2012088019A patent/SG186109A1/en unknown
- 2011-05-20 AU AU2011261684A patent/AU2011261684B2/en active Active
- 2011-05-20 JP JP2013513207A patent/JP2013527232A/ja active Pending
- 2011-05-20 ES ES11790192.6T patent/ES2639038T3/es active Active
- 2011-05-20 NZ NZ708506A patent/NZ708506A/en unknown
- 2011-05-20 NZ NZ604029A patent/NZ604029A/en unknown
- 2011-05-20 US US13/701,003 patent/US20130266659A1/en not_active Abandoned
- 2011-05-20 PH PH1/2012/502378A patent/PH12012502378A1/en unknown
- 2011-05-20 CN CN201180038029.3A patent/CN103221042B/zh active Active
- 2011-05-20 BR BR112012030699A patent/BR112012030699A2/pt not_active Application Discontinuation
- 2011-05-20 RU RU2012157805A patent/RU2621640C2/ru active
-
2012
- 2012-11-22 ZA ZA2012/08815A patent/ZA201208815B/en unknown
- 2012-11-30 NI NI201200175A patent/NI201200175A/es unknown
- 2012-12-10 CR CR20120619A patent/CR20120619A/es unknown
- 2012-12-28 CO CO12236221A patent/CO6620019A2/es unknown
-
2013
- 2013-03-01 US US13/782,984 patent/US20140056986A1/en not_active Abandoned
-
2016
- 2016-10-18 PH PH12016502066A patent/PH12016502066A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013527232A5 (enExample) | ||
| JP2011079858A5 (enExample) | ||
| JP2013503174A5 (enExample) | ||
| RU2012157805A (ru) | Способы лечения рака мочевого пузыря | |
| JP2013527233A5 (enExample) | ||
| JP2016513657A5 (enExample) | ||
| Aditya et al. | Advances in nanomedicines for malaria treatment | |
| JP2012506448A5 (enExample) | ||
| JP2017025090A5 (enExample) | ||
| JP2010180210A5 (enExample) | ||
| JP2011515481A5 (enExample) | ||
| JP2014532704A5 (enExample) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2017214436A5 (enExample) | ||
| JP2015515475A5 (enExample) | ||
| JP2010529025A5 (enExample) | ||
| JP2010509331A5 (enExample) | ||
| JP2008530248A5 (enExample) | ||
| JP2014148535A5 (enExample) | ||
| FI4403228T3 (fi) | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote | |
| JP2013523656A5 (enExample) | ||
| JP2016512513A5 (enExample) | ||
| JP2012517449A5 (enExample) | ||
| JP2013542205A5 (enExample) | ||
| JP2019521180A5 (enExample) |